Focused On-demand Library for Lysosomal enzyme trafficking factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N6I4

UPID:

LYSET_HUMAN

Alternative names:

GNPTAB cleavage and activity factor; Transmembrane protein 251

Alternative UPACC:

Q8N6I4; J3KQ65; Q9Y4S5

Background:

The Lysosomal enzyme trafficking factor, also known as GNPTAB cleavage and activity factor or Transmembrane protein 251, plays a pivotal role in mannose-6-phosphate-dependent trafficking of lysosomal enzymes. It acts as a bridge for the proteolytic activation of GNPTAB, crucial for Golgi-to-lysosome transport of lysosomal enzymes, and is indispensable for the maturation and delivery of lysosomal hydrolases.

Therapeutic significance:

Linked to Dysostosis multiplex, Ain-Naz type, a severe skeletal disease, understanding the role of Lysosomal enzyme trafficking factor could open doors to potential therapeutic strategies.